NCT02120976View on ClinicalTrials.gov

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

PHASE1TerminatedINTERVENTIONAL

Enrollment

85

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

March 31, 2015

Conditions

Diabetes Mellitus

Interventions

DRUG

JTT-252 or Placebo

Subjects will receive JTT-252 or Placebo

DRUG

JTT-252

Subjects will receive JTT-252

Trial Locations (2)

Unknown

Overland Park

Austin

Sponsors

Lead Sponsor

Akros Pharma Inc.

All Listed Sponsors

lead

Akros Pharma Inc.

INDUSTRY

NCT02120976 - Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252 | Biotech Hunter | Biotech Hunter